Brain Malignancies Steering Committee
The NCI Brain Malignancies Steering Committee (BMSC) was established in November of 2010.
The BMSC functions to harmonize an efficient, cost-effective, science-driven, and transparent process that will identify and promote the "Best Science" in brain cancer clinical research by addressing the design, prioritization and evaluation of phase 2, and phase 3 clinical trials in both adult and pediatric brain cancers.
Clinical Trials Planning Meetings (CTPMs)
- Improving the Treatment of Glioblastoma CTPM - September 2013
The following are clinical trials that were approved at the concept stage by the Steering Committee.
|Trial ID||NCT ID||Trial Title|
|PBTC-039||NCT01964300||Phase II study of Peginterferon α-2b for Pediatric Patients with Unresectable or Recurrent Craniopharyngioma|
|COG-ACNS1221||NCT02017964||A Phase II Study For The Treatment Of Non-Metastatic Nodular Desmoplastic Medulloblastoma In Children Less Than 4 Years Of Age|
|COG-ACNS1123||NCT01602666||A Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors|
|Alliance-A071101||NCT01814813||A Phase 2 Multicenter, Randomized, Double Blind, Placebo-Controlled Trial Comparing Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) Vaccine or Placebo in Combination with Bevacizumab (Avastin®) in the Therapy of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)|
|PBTC-036||NCT01836549||A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children with Recurrent High-Grade Glioma, Ependymoma, Medulloblastoma/Primitive Neuroectodermal Tumor (PNET) and Diffuse Intrinsic Pontine Glioma (GBM)|
|RTOG-1205||NCT01730950||A Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma|
|COG-ACNS1022||NCT01553149||A Phase II Trial of Lenalidomide in Pediatric Patients with Recurrent, Refractory or Progressive Low-Grade CNS Gliomas|
|PBTC-033||NCT01514201||A Feasibility and Phase II Study of ABT888, an oral poly( ADP-ribose) polymerase inhibitor, and concurrent radiation therapy, followed by ABT888 and temozolomide, in children with newly diagnosed high-grade or diffuse pontine gliomas (DIPG)|
CCCT Contact: Abdul Tawab Amiri, Ph.D